Hoit B D, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh R A
Division of Cardiology, University of Cincinnati Medical Center, Ohio 45267-0542, USA.
J Clin Invest. 1995 Apr;95(4):1519-27. doi: 10.1172/JCI117824.
Human chymase is a serine proteinase that converts angiotensin (Ang) I to Ang II independent of angiotensin converting enzyme (ACE) in vitro. The effects of chymase on systemic hemodynamics and left ventricular function in vivo were studied in nine conscious baboons instrumented with a LV micromanometer and LV minor axis and wall thickness sonomicrometer crystal pairs. Measurements were made at baseline and after [Pro11DAla12] Ang I, a specific substrate for human chymase, was given in consecutive fashion as a 0.1 mg bolus, an hour-long intravenous infusion of 5 mg, a 3 mg bolus, and after 5 mg of an Ang II receptor antagonist. [Pro11DAla12]Ang I significantly increased LV systolic and diastolic pressure, LV end-diastolic and end systolic dimensions and the time constant of LV relaxation and significantly decreased LV fractional shortening and wall thickening. Administration of a specific Ang II receptor antagonist reversed all the hemodynamic changes. In separate studies, similar results were obtained in six of the baboons with ACE blockade (20 mg, intravenous captopril). Post-mortem studies indicated that chymase-like activity was widely distributed in multiple tissues. Thus, in primates, Ang I is converted into Ang II by an enzyme with chymase-like activity. This study provides the first in vivo evidence of an ACE-independent pathway for Ang II production.
人糜酶是一种丝氨酸蛋白酶,在体外可独立于血管紧张素转换酶(ACE)将血管紧张素(Ang)I转换为Ang II。在9只清醒的狒狒中进行了研究,这些狒狒植入了左心室微测压计以及左心室短轴和壁厚超声微测晶体对,以观察糜酶对体内全身血流动力学和左心室功能的影响。在基线时以及连续给予人糜酶的特异性底物[Pro11DAla12]Ang I后进行测量,给药方式依次为0.1 mg推注、5 mg长达1小时的静脉输注、3 mg推注以及在给予5 mg Ang II受体拮抗剂之后。[Pro11DAla12]Ang I显著增加了左心室收缩压和舒张压、左心室舒张末期和收缩末期内径以及左心室舒张时间常数,并显著降低了左心室缩短分数和室壁增厚。给予特异性Ang II受体拮抗剂可逆转所有血流动力学变化。在单独的研究中,6只接受ACE阻断(静脉注射20 mg卡托普利)的狒狒也得到了类似结果。尸检研究表明,糜酶样活性广泛分布于多种组织中。因此,在灵长类动物中,Ang I可通过具有糜酶样活性的酶转化为Ang II。本研究首次提供了体内存在不依赖ACE的Ang II生成途径的证据。